Glaucoma Eye Drops: Drug Classes Explained

Learn how glaucoma eye drops lower IOP, how the four main drug classes work and which combinations matter for board exams.

Reviewed for accuracyAugust 9, 20263 min read

Warm-up

Which class of glaucoma medication primarily increases uveoscleral outflow?

Lesson

Glaucoma Eye Drops in 30 Seconds

Glaucoma eye drops lower intraocular pressure to slow optic nerve damage and visual field loss. They belong to distinct drug classes with different mechanisms, so selecting the right class or combination depends on mechanism, efficacy and patient comorbidities.

The Four Main Drug Classes

Prostaglandin analogs (latanoprost, bimatoprost, travoprost): FP receptor agonism increases uveoscleral outflow. IOP reduction 20 to 35%, the most effective class. Once daily. Key side effects: iris pigmentation, periorbital changes, hypertrichosis. First-line for most patients.

Beta-blockers (timolol, betaxolol): reduce aqueous production by the nonpigmented ciliary epithelium. IOP reduction 20 to 25%. Twice daily, morning preferred. Contraindicated in asthma and generally avoided in significant COPD, bradycardia or heart block. Second-line after prostaglandins.

Carbonic anhydrase inhibitors (dorzolamide, brinzolamide, acetazolamide): inhibit carbonic anhydrase and reduce aqueous production. Topical IOP reduction 15 to 20%. Twice or three times daily. Avoid or use extreme caution with oral agents in sickle cell disease because metabolic acidosis may promote sickling. Used as an adjunct.

Alpha-2 agonists (brimonidine, apraclonidine): reduce aqueous production and increase uveoscleral outflow. IOP reduction 20 to 25%. Twice or three times daily. Brimonidine is contraindicated in children under 2 years. Used as an adjunct.

Combining Drug Classes

Fixed combinations: Cosopt (dorzolamide plus timolol), Combigan (brimonidine plus timolol) and Simbrinza (brimonidine plus brinzolamide). Exam relevance: fewer bottles improve adherence and reduce the number of daily instillations.
Combining two agents from the same class generally provides little additional IOP reduction because they share overlapping mechanisms of action. Exam relevance: drug class selection matters more than simply adding another drop.
Prostaglandin plus beta-blocker is the most common first-step combination. Exam relevance: different mechanisms produce additive IOP lowering.
Combining medications from different classes produces additive IOP lowering because each acts through a distinct mechanism. Exam relevance: this is the rationale for stepwise combination therapy.

4 Facts Exams Always Ask

Prostaglandin analogs are first-line because of once-daily dosing and 20 to 35% IOP reduction via uveoscleral outflow.
Combining two medications from the same class provides little additional IOP reduction because they have overlapping mechanisms of action.
Timolol is contraindicated in asthma and generally avoided in significant COPD; betaxolol is the beta-1 selective alternative when a beta-blocker is necessary.
Brimonidine is absolutely contraindicated in children under 2 years due to CNS and respiratory depression.

The Classic Trap

Two common traps: combining two drugs from the same class and expecting additive IOP reduction when overlapping mechanisms limit the benefit, and prescribing timolol in a patient with asthma or significant COPD without considering a CAI or alpha-2 agonist instead. A third trap is using pilocarpine as a first-line agent when it is now reserved for selected indications rather than routine first-line treatment.

Clinical Pearl

The standard approach is prostaglandin first, then add a second class such as a CAI or alpha-2 agonist if target IOP is not met. Fixed combinations improve adherence. Selective laser trabeculoplasty is an effective first-line or adjunctive option and may reduce or eliminate the need for topical medications in some patients. Each class works by a different mechanism, so combining different classes produces additive IOP lowering.

Check yourself

Checkpoint 1

A key pharmacodynamic reason fixed-combination glaucoma drops (e.g., timolol-dorzolamide) are preferred over concurrent separate instillation of the same two drugs is:

Checkpoint 2

Timolol belongs to which class of glaucoma medication?

Clinical case

A patient using latanoprost needs additional IOP lowering. The patient has asthma but no other relevant medical history. Which add-on drug class is most appropriate?

A patient with POAG on latanoprost has uncontrolled IOP and has asthma. Which add-on drug class is most appropriate?

Explanation

A topical CAI reduces aqueous production through a different mechanism from latanoprost and provides additive IOP lowering without beta-adrenergic blockade. Timolol and other non-selective beta-blockers are contraindicated in asthma because beta-2 blockade causes bronchospasm. Adding a second prostaglandin provides minimal additional benefit due to overlapping mechanisms. If a beta-blocker is needed, betaxolol requires caution but is relatively safer.

Case discussion

Add a topical CAI such as dorzolamide or brinzolamide, because it reduces aqueous production through a different mechanism and provides additive IOP lowering without beta-adrenergic blockade. Timolol should be avoided in asthma since beta-2 blockade causes bronchospasm. Adding a second prostaglandin provides minimal additional benefit due to overlapping mechanisms. If a beta-blocker is essential, betaxolol requires caution but is relatively safer than timolol in pulmonary disease.

Sources & Publisher Info

Published by Vasilis Inglezis, Optometrist and Ocular Oncology Imaging Specialist. Last updated August 9, 2026.

Last clinically reviewed: August 9, 2026

References

American Academy of Ophthalmology. Basic and Clinical Science Course, Section 10: Glaucoma.
American Academy of Ophthalmology. EyeWiki: Glaucoma Medical Therapy.

Continue learning

Ready for the real thing?

Practice thousands of eye-care questions free on OcuQuiz. Earn points, build streaks and battle colleagues.

Practice Pharmacology →